APR 07, 2016 10:00 AM PDT

Molecular Medicine in Healthcare: The Personalized Medicine Initiative

C.E. CREDITS: P.A.C.E. CE
Speakers
  • Chair, Personalized Medicine Initiative, Director, Life Sciences Institute, University of British Columbia
    Biography
      Dr. Pieter Cullis completed his PhD in Physics at the University of British Columbia (UBC) in 1972 and then pursued postdoctoral training in biochemistry at the University of Oxford as an MRC postdoctoral fellow and at the University of Utrecht as a fellow of the European Molecular Biology Organization. He joined the Department of Biochemistry and Molecular Biology at UBC in 1978 and was appointed professor in 1985.

      Dr. Cullis is an internationally recognized pioneer and leader in the field of lipids, biological membranes and liposomal drug delivery systems. His drug delivery systems have produced improved formulations of several cancer therapies as well as other drug agents. His lipid nanoparticles delivery system is a leading technology worldwide, enabling the therapeutic potential of siRNA. He has published over 300 scientific articles.

      He has been very active in the development of several biotechnology companies and is recognized as a remarkable researcher and innovator. His work has led to three drugs that have been approved by regulatory agencies in the U.S. and Europe for the treatment of cancer and its complications and five more that have finished Phase I clinical studies. He has trained many graduate students and postdoctoral fellows, several of whom have gone on to distinguished careers in their own right.

      Dr. Cullis co-founded The Canadian Liposome Company, Inex Pharmaceuticals (now Tekmira Pharmaceuticals), Northern Lipids Inc., Lipex Biomembranes Inc., and, most recently, Acuitas Pharmaceuticals, Precision NanoSystems and Mesentech Inc. In addition, he co-founded and was Scientific Director of the Centre for Drug Research and Development (CDRD) 2004-2010. He has been part of management teams that have raised over $200M in the biotechnology sector in BC. He is an inventor on over 40 patents.

    Abstract:

    The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines of healthcare. The PMI is taking advantage of new technologies that increasingly allow individuals to be analyzed at the molecular level in a rapid and cost-effective manner. These analyses  enables both effective preventive medicine as more precise diagnostics to accurately match therapy to disease. The PMI is pursuing an “end-to-end” approach. First, the PMI has developed the resources necessary to construct the genomic, proteomic, metabolomic and microbiomic “data clouds” around individuals to determine their risks of disease, diagnose overt disease and monitor response to therapy. These “molecular you” profiles are now being generated by a PMI company called the Molecular You Corporation (MYCO). Second, in order to use molecular level information clinicians require clinical decision support systems (CDSS) to assist them in deciding on the most appropriate therapy. Again, the PMI has formed a company called GenXys to develop CDSS to assist the prescription practices of family doctors. The MYCO molecular you profiles are proving remarkably useful for early detection of disease and to guide lifestyle and diet changes to correct trends towards disease. GenXys, on the other hand, is commercializing a simple genetic test to guide drug prescription to avoid adverse drug reactions. This is achieved by construction of algorithms that incorporate genetic information together with standard clinical information to guide prescription of over 200 commonly prescribed drugs. 

    Learning Objectives:

    1. Integrated Omics (proteomic, genomic, microbiomic, metabolomic) profiling can be of use for empowering individuals to practice more effective preventive healthcare.
    2. Molecular level information can be used by family physicians to assist in drug prescription on an individualized basis.

    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources